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This brief review recounts how systolic hypertension came
to be recognized as an important determinant of cardiovas-
cular disease, beginning with the publication of a Framing-
ham data-based article in the American Journal of Cardiology
in April 1971.
Systolic Versus Diastolic
Blood Pressure and
Risk of Coronary Heart Disease
The Framingham Study
by Kannel, Gordon and Schwartz (1)
ABSTRACT
A comparison of the contribution of systolic versus diastolic blood
pressure to risk of coronary heart disease and the role of mean
arterial pulse pressure and systolic lability have been examined
prospectively in 5,127 men and women during 14 years of
biennial follow-up studies.
Similar gradients of risk of subsequent coronary heart disease
were observed whether persons were classified by their systolic or
diastolic pressure, and no “safe” or critical level could be
identified. Assessment of the net effect of each, employing
discriminant analysis, indicated a stronger association of systolic
than diastolic pressure with risk of coronary heart disease.
Neither the systolic and diastolic pressure measurements in
combination nor the pulse pressure and the mean arterial
pressure measurements alone discriminated better than the
systolic measurement alone. Systolic lability did not predict
incidence of coronary heart disease independently of the associ-
ated level of blood pressure.
There was a trend of declining relative importance of diastolic
and a corresponding increase in the importance of systolic
pressure with advancing age. Only in those under 45 was
diastolic pressure predominant. The level of casually obtained
blood pressure was a good predictor of coronary heart disease.
The current practice of assessing the importance of blood pressure
at all ages largely on the basis of diastolic pressure and the
commonly held view concerning the innocuous nature of an
elevated level of systolic pressure in the elderly requires reeval-
uation.
Originally published in American Journal of Cardiology, April 1971
Review
SYSTOLIC HYPERTENSION AS A CV RISK FACTOR—
HAS IT FINALLY BEEN ACCEPTED?
In 1971 Kannel, Gordon and Schwartz published a paper
showing systolic blood pressure to be a better predictor of
coronary heart disease than diastolic pressure (1). That
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INTRODUCTION
In this edition of the Journal, we release the third in a series of
reviews of influential articles that have been previously pub-
lished in ACC journals, including the American Journal of
Cardiology (from 1958 to 1982), and JACC (from 1983 to the
present). The publication of these articles is only one aspect of
the ACC’s 50th anniversary commemoration, which highlights
50 years of leadership in cardiovascular care and education. The
articles are intended to encourage reflection on the remarkable
progress made in cardiovascular medicine over time, as well as
to acknowledge the amazing prescience of some early investi-
gators in anticipating and, in many cases, later guiding devel-
opments in their field.
The working group responsible for selecting these articles and
asking reviewers to write editorials solicited suggestions from
the ACC’s clinical committees and individual members.
The group achieved consensus fairly easily, including whom the
group should ask to prepare the accompanying editorials. We
initially drew up a list of 14 general areas to cover in this series,
but later found that there are several major areas of modern
cardiology, prominently molecular cardiology, in which the
truly landmark articles have, alas, not yet been published in
JACC. Therefore, the working group decided not to categorize
by subject, but instead, to concentrate on the most important
articles.
The working group, a task force of the Subcommittee for the
Commemoration of the ACC 50th Anniversary, owes a great
deal to Ms. May A. Roustom and the efficient and tireless staff
at Heart House for facilitating this project. We also wish to
thank all who suggested articles and, most important, the
authors who prepared reviews for their willingness to contribute
their time and wisdom.
Influential Articles in JACC Working Group
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paper was the beginning of a change in attitude towards
systolic hypertension which for years had been considered
physiologically insignificant.
Now, 28 years later, systolic pressure is given more
emphasis than diastolic pressure (2) and the importance
of the latter is at times trivialized (3). Twenty-eight years
seems a long time for a concept to become firmly
established and one wonders why, particularly since the
1971 paper was based on Framingham data which have
formed the basis of most of our principles of preventive
cardiology. This is not the first time hypertension has
been slow to be accepted as a health problem and it seems
to have chronic ill luck in that regard (ill luck for
patients) of being slow in becoming accepted as an
abnormality carrying significant risks for premature car-
diovascular morbidity and mortality. Twenty-eight years
may be a long time, but it is substantially less than the 59
years from the 1913 report by Janeway of the fatal
complications of hypertension (4) and the 1972 begin-
nings of the National High Blood Pressure Education
Program (NHBPEP) which successfully promoted hy-
pertension as a major public health problem highly
responsive to medical treatment.
Between 1913 and 1972 lots of things happened which
were finally responsible for putting hypertension on the
list of diseases that respond favorably to treatment and
that doctors should treat. First, hypertension had to be
recognized as a serious, though often symptomless, ill-
ness. There were some long term follow-up reports, but
the most compelling evidence came from insurance data.
These were published in 1925 (5) and 1940 (6), but most
doctors were not impressed. This lack of interest may
have reflected a lack of effective treatment. The few
doctors who did recognize hypertension as a serious
public health problem looked for therapies and early
treatments, which gave some relief to the few patients
who received them, such as lumbodorsal sympathectomy,
low sodium diets and pyrogen therapy.
The breakthrough came in 1951 when drugs became
available that were orally active and had long-term effec-
tiveness. The patients that were treated at first were those
with severe diastolic hypertension. Diastolic hypertension
was the focus of attention because these people died young.
Systolic hypertension received no real attention because it
was found mostly in old people who, unlike today, were not
expected to live long lives. Actually, systolic pressure was
thought to increase as a natural process of aging so doctors
simply disregarded it; it was the young and middle-aged
people with severe diastolic hypertension that concerned
them.
Although the successful drug treatment of malignant
hypertension was impressive to the few doctors respon-
sible (7,8), it was the results of the VA Cooperative Trials
that were decisive in changing public policy (9,10). They
showed without question that treating diastolic blood
pressures of 104 to 129 mm Hg protected against
development of strokes, cardiac failure and worsening
hypertension. These were the data that sparked develop-
ment of the NHBPEP which through a broad based
public and professional education program has been
responsible for striking decreases in deaths from strokes
and heart attacks.
All this time nobody but a few thought anything about
systolic hypertension. Some had tried (11,13) going back as
far as 1927 (11), but the data were disregarded; doctors
were too preoccupied with the need to treat diastolic
hypertension.
By 1971 doctors had learned to respect data from the
Framingham study. After all it had clearly delineated the
many risk factors for coronary heart disease and doctors,
with varying degrees of enthusiasm, were prescribing low
fat diets, urging weight loss and using drugs to control
diabetes and hyperlipidemia, advising smoking cessation
and treating hypertension. Yet, apparently as much as
they respected the multiple risk factor basis for coronary
heart disease, they were not ready to accept systolic
hypertension as a better predictor of coronary heart
disease than diastolic hypertension. Also, the drugs
available in the 1970s were thought not to be effective in
lowering systolic blood pressure.
Slowly a change in attitude came as systolic hyperten-
sion was found to be more important than diastolic
pressure in strokes, heart failure and peripheral vascular
disease (14). Furthermore, a 1988 longitudinal study of
the 317,871 men who had been screened for the Multiple
Risk Factor Intervention Trial (15) confirmed the find-
ings of the Framingham study. Thus, evidence support-
ing systolic hypertension as an important determinant of
cardiovascular disease became almost impossible to ig-
nore. A sign of this change in attitude is the Fifth Report
of the National Committee on Detection, Evaluation and
Treatment of Hypertension (JNC 5) (16) which by 1993
had included systolic blood pressure in the classification
of blood pressure giving it equal billing with diastolic
pressure. Another important report was that of the
Systolic Hypertension in the Elderly Program (SHEP)
(17) which showed that systolic blood pressure could be
decreased significantly by chlorthalidone and, if neces-
sary, the addition of atenolol and that this reduction
protected against strokes and other complications of
hypertension.
How are doctors responding to this challenge 28 years
and much more evidence later? We do not know for sure,
but we do know that 10 years ago New Jersey cardiologists
did not treat isolated systolic hypertension as often as did
internists and family physicians (18). But that was 10 years
ago and one can hope that a cavalier attitude towards
systolic hypertension has generally been discarded.
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